Sclerotherapy Training for Aesthetic Providers: What to Know Before Adding It

Providers researching sclerotherapy courses tend to focus on injection technique and patient volume potential. Fewer ask which specific agents they’ll be trained to use, and whether those agents are actually approved for the purpose being taught.

Polidocanol, sold as Asclera, and sodium tetradecyl sulfate are FDA-approved for spider and reticular veins. Hypertonic saline and 72% chromated glycerin, both still referenced in some training content, are not FDA-approved for this specific use in the US, despite being used historically and, in glycerin’s case, more commonly in Europe.

That distinction matters for a sclerotherapy certification the same way FDA device clearance matters for microneedling or laser: it’s not a technicality; it’s the line between a defensible clinical decision and one that isn’t.

This blog breaks down what a sclerotherapy training course should actually cover, the cosmetic-versus-medical distinction that shapes scope and billing, and what patients can realistically expect from treatment.

For the full curriculum, ABACT’s Sclerotherapy Certification Online Course covers vein diagnosis, mapping, agent selection, and injection technique in a self-paced format.

Only Two Sclerosants Are Actually FDA-Approved for This in the US

This is the detail that separates rigorous sclerotherapy training from training that repeats historical practice without checking current approval status.

Polidocanol and STS Hold FDA Approval; Saline and Glycerin Do Not

Polidocanol, marketed as Asclera, and sodium tetradecyl sulfate are the two agents currently FDA-approved for treating spider and reticular veins in the United States. Hypertonic saline remains in some use but is not FDA-approved for this indication, carries a documented pain and staining risk, and is not effective on larger reticular veins. Chromated glycerin, popular in parts of Europe, has likewise not received FDA approval for sclerotherapy use in the US.

Dosing Is Concentration-Specific, Not a Single Universal Protocol

Asclera’s FDA prescribing label specifies 0.5% concentration for spider veins under 1mm in diameter and 1% concentration for reticular veins between 1 and 3mm, with a maximum recommended volume of 10mL per treatment session. Training that teaches a single generic injection protocol without this concentration-by-vein-size distinction is teaching an incomplete picture.

Real Outcome Data Shows a Wide but Predictable Session Range

A published clinical review of roughly 1,600 sclerotherapy sessions using 0.5% polidocanol found an average of 3 sessions produced 80 to 85 percent improvement in treated veins, with the total range across patients spanning 1 to 15 sessions depending on the extent of the condition. Complications in that dataset were limited mostly to localized thrombus formation and hyperpigmentation, without serious adverse events like ulceration or embolism.

What a Sclerotherapy Training Course Should Actually Cover

Technique alone isn’t enough; the clinical judgment behind agent and concentration selection is what training actually needs to build.

Cosmetic vs. Medical Vein Assessment Belongs Early in the Curriculum

A strong sclerotherapy certification course teaches providers to distinguish cosmetic spider veins from venous reflux disease that may be medically significant, since that distinction affects whether ultrasound evaluation is warranted, whether a referral is appropriate, and whether the treatment is billable as a medical service rather than an out-of-pocket cosmetic one.

Verifying the specific product or agent behind a training program, not just the modality name, is a habit worth building across every injectable service line, not just sclerotherapy. ABACT’s PRP training and certification guide applies the same scrutiny to platelet-rich plasma training.

For providers looking for structured training before adding sclerotherapy to their practice, ABACT offers an Online Sclerotherapy Course covering vein assessment, sclerosant selection, treatment considerations, and injection technique in a self-paced format.

Is Sclerotherapy Training Worth Adding to Your Practice

Only two sclerosant agents, polidocanol (brand name Asclera) and sodium tetradecyl sulfate, are FDA-approved for treating spider and reticular veins in the US. Commonly referenced alternatives like hypertonic saline and chromated glycerin are not. Sclerotherapy training should teach this distinction explicitly, along with the difference between cosmetic spider veins and medically significant venous reflux disease, since that distinction affects both technique and whether treatment is billable to insurance. Most patients need 2 to 4 sessions, though clinical data shows a range of 1 to 15 depending on severity.

The demand case is straightforward; the fit depends more on existing patient population than on training cost.

A High-Prevalence, Low-Complexity Addition for the Right Practice

An estimated majority of women over 20 have some degree of unwanted leg veins, and the large majority of those cases are cosmetic rather than medically urgent. For practices already offering injectable aesthetic services, sclerotherapy training for physicians and sclerotherapy training for nurse practitioners alike represents a relatively contained skill addition: the injection technique itself is less anatomically complex than facial injectables, though the vein assessment and agent selection judgment still requires real training, not a weekend overview.

Most providers asking about varicose vein training course options are trying to determine whether their existing scope of practice already covers this or whether additional credentialing is required. That answer depends on state-specific rules for your license type, which is worth confirming before enrolling rather than after.

In our experience working with sclerotherapy training for nurses adding injectable service lines, the ones who verify sclerosant approval status and cosmetic-versus-medical assessment protocols upfront spend less time later correcting documentation gaps that insurers and malpractice carriers both tend to flag.

Final Verdict: Train on Named, Approved Agents, Not Generic Technique

The sclerotherapy training courses are worth adding for aesthetic providers in 2026, provided it names the specific sclerosants taught, confirms their FDA approval status, and teaches the cosmetic-versus-medical distinction as core curriculum rather than an aside.

This is a strong fit for practices with an existing injectable patient base looking to add a lower-complexity service, less so as a first modality for someone entirely new to aesthetic injections. Confirming which agents your training actually covers, and whether they carry FDA approval, is what separates informed practice from inherited habit.

Explore the full sclerotherapy course online with certification and curriculum details at our official ABACT.

FAQs